Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-882-5 | CAS number: 3268-49-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Gene mutation in bacteria (according to OECD 471, Ames test): negative in S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 uvrA with and without metabolic activation
Gene mutation in mammalian cells in vitro (OECD 476, Mouse lymphoma assay): positive in mouse lymphoma L5178Y cells with and without metabolic activation, genotoxic effect attributed to impurity acrolein
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- adopted July 21, 1997
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- The Salmonella typhimurium histidine (his) and the Escherichia coli tryptophan (trp) reversion system measures his-→ his+ and trp-→ trp+ reversions, respectively.
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Metabolic activation system:
- Cofactor supplemented post-mitochondrial fraction (S9 mix), prepared from the livers of rats treated with phenobarbital/ß-naphtoflavone.
- Test concentrations with justification for top dose:
- In a pre-experiment a concentration range of the test item was 3 – 5000 μg/plate. The pre-experiment is reported as experiment I. Since toxic effects were observed in experiment I, eight concentrations were tested in experiment II. 5000 μg/plate were chosen as maximal concentration. The concentration range included two logarithmic decades. The following concentrations were tested in experiment II: 3; 10; 33; 100; 333; 1000; 2500; and 5000 μg/plate.
Experiment 1 (plate incorporation test) and Experiment 2 (preincubation test): 3, 10, 33, 100, 333, 1000, 2500 and 5000 µg/plate, with and without metabolic activation - Vehicle / solvent:
- - Vehicle/solvent used: DMSO
- Justification for choice of solvent/vehicle: The solvent has been chosen according to its solubility properties and its relative nontoxicity to the bacteria. - Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- methylmethanesulfonate
- other: 2-aminoanthracene dissolved in DMSO; for TA 1535, TA 1537, TA 98, TA 100, WP2 uvrA; +S9 // 4-nitro-o-phenylene-diamine, 4-NOPD dissolved in DMSO; for TA 1537, TA 98; -S9
- Details on test system and experimental conditions:
- NUMBER OF REPLICATIONS:
- Number of cultures per concentration: triplicate
METHOD OF TREATMENT/ EXPOSURE:
- Test substance added in agar (plate incorporation); preincubation
TREATMENT AND HARVEST SCHEDULE:
- Preincubation period: 60 min
- Exposure duration/duration of treatment: 48 hours at 37 C ± 1.5° C in the dark
METHODS FOR MEASUREMENT OF CYTOTOXICITY
- Method: background growth inhibition
METHODS FOR MEASUREMENTS OF GENOTOXICIY
- Method: Number of revertant colonies - Evaluation criteria:
- A test item is considered as a mutagen if a biologically relevant increase in the number of revertants of twofold or above (strains TA 98, TA 100, and WP2 uvrA) or threefold or above (strains TA 1535 and TA 1537) the spontaneous mutation rate of the corresponding solvent control is observed. A dose dependent increase is considered biologically relevant if the threshold is reached or exceeded at more than one concentration. An increase of revertant colonies equal or above the threshold at only one concentration is judged as biologically relevant if reproduced in an independent second experiment. A dose dependent increase in the number of revertant colonies below the threshold is regarded as an indication of a mutagenic potential if reproduced in an independent second experiment. However, whenever the colony counts remain within the historical range of negative and solvent controls such an increase is not considered biologically relevant.
- Statistics:
- Mean values and standard deviation were calculated.
- Key result
- Species / strain:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 uvrA
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- in all strains at higher concentrations with and without metabolic activation
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation and time of the determination: No precipitation of the test item occurred in the overlay agar in the test tubes. Precipitation of the test item in the overlay agar on the incubated agar plates was observed at 5000 μg/plate.
STUDY RESULTS
- Concurrent vehicle negative and positive control data
Ames test:
- Signs of toxicity , Individual plate counts , Mean number of revertant colonies per plate and standard deviation : Refer to Table no. 1 and 2 under "Any other information on results incl. tables".
HISTORICAL CONTROL DATA
- Positive historical control data: yes
- Negative (solvent/vehicle) historical control data: yes - Conclusions:
- Interpretation of results: negative with and without metabolic activation, no mutagenic potential was detected in the bacterial reverse mutation assay.
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- adopted 21 Jul 1997
- Deviations:
- yes
- Remarks:
- not tested in TA102 or E. coli WP2 uvrA; 2-aminoanthracene as sole positive control for all strains, no historical control data, no justification for lack of a confirmatory experiment, not tested up to cytotoxic/precipitation limit concentrations
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- The S. typhimurium histidine (his) reversion system measures his- --> his+ reversions. The S. typhimurium strains are constructed to differentiate between base pair (TA 1535, TA 100) and frameshift (TA 1537, TA 98) mutations.
- Species / strain / cell type:
- other: S. typhimurium TA1535, TA1537, TA1538, TA98 and TA100
- Metabolic activation:
- with and without
- Metabolic activation system:
- Cofactor supplemented post-mitochondrial fraction (S9 mix), prepared from the livers of rats treated with Arochlor 1254.
- Test concentrations with justification for top dose:
- 0.01, 0.0316, 0.1 and 0.316 µg/plate for all strains with and without metabolic activation
- Vehicle / solvent:
- - Vehicle/solvent used: DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- 9-aminoacridine
- sodium azide
- other: 2-anthramine (2-AM), +S9, 2.5 µg/plate for all strains
- Details on test system and experimental conditions:
- NUMBER OF REPLICATIONS:
triplicates in a single experiment
METHOD OF TREATMENT: pre-incubation
DURATION
- Preincubation period: 20 min
- Exposure duration: 48 h at 37 °C
METHODS FOR MEASUREMENT OF CYTOTOXICITY
- Method: Inspection of the bacterial background lawn
METHODS FOR MEASUREMENTS OF GENOTOXICIY :
- Method: Number of revertant colonies
- Species / strain:
- other: S. typhimurium TA 1535, TA 1537, TA 1538, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- at 0.1 µg/plate with and without metabolic activation
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES:
A dose-rage finding pre-incubation test was performed with tester strain TA100 with concentrations up to 10 µg/plate in the presence and absence of metabolic activation.
In a pre-incubation assay, four log dilutions of the test substance, to a maximum concentration of 10 µl/plate, were tested. The pre-test was performed with strain TA100 in a concentration range-finding test, with and without metabolic activation. A concentration-related increase in toxicity was observed at 0.1 µg/plate and above.
STUDY RESULTS
- No concentration-related increase in mean histidine revertant colonies/plate was observed for any strain in the absence or presence of metabolic activation.
- Concentration-response relationship: There was no dose-response relationship observed for any test concentration with and without metabolic activation.
- Signs of toxicity: Cytotoxicity was evident by a significant reduction in colonies at 0.316 µl/plate for strain TA1537 in the absence of activation, for all concentrations of test substance strain TA1537 in the presence of activation and for all concentrations of the test substance in strain TA100 in the absence of metabolic activation.
- Concurrent vehicle negative and positive control data: All positive and negative controls gave the expected results and were consistent with those reported in the literature. Historical control data were not reported.
- Mean number of revertant colonies per plate and standard deviation: Refer to Table no. 1 under "Any other information on results incl. tables". - Conclusions:
- Interpretation of results: negative
The test substance did not show mutagenic activity in Salmonella typhimurium TA1535, TA1537, TA1538, TA98 or TA100 with and without metabolic activation. - Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- adopted 29 Jul 2016
- Deviations:
- yes
- Remarks:
- limited information on experimental details and raw data of individual replicates
- GLP compliance:
- not specified
- Type of assay:
- in vitro mammalian cell gene mutation tests using the thymidine kinase gene
- Target gene:
- mouse lymphoma thymidine kinase locus
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- CELLS USED
- Type and source of cells: L5178Y mouse lymphoma cells, clone 3.7.2c
For cell lines:
- Periodically ‘cleansed’ of spontaneous mutants: yes
MEDIA USED
- Type and composition of media, CO2 concentration, humidity level, temperature: The cells were cultivated in Fisher's medium supplemented with 31 µg penicillin/mL, 50 µg streptomycin sulfate/mL, 0.1% pluronic F68, 0.22 mg sodium pyruvate/mL, 25 mM HEPES buffer. In the absence of metabolic activation 10% heat-inactivated horse serum were added, in the absence of metabolic activation 5% heat-inactivated horse serum were added. - Metabolic activation:
- with and without
- Metabolic activation system:
- Cofactor supplemented post-mitochondrial fraction (S9 mix), prepared from the livers of rats treated with Arochlor 1254.
- Test concentrations with justification for top dose:
- Experiment 1:
Without S9 mix: 0.0001, 0.01, 0.0178, 0.0316 and 0.0562 µL/mL (4 h)
With S9 mix: 0.0562, 0.1, 0.178, 0.316 and 0.562 µL/mL (4 h)
Experiment 2:
Without S9 mix: 0.001, 0.01, 0.015, 0.02, 0.025, 0.03, 0.035 and 0.04 µL/mL (4 h)
With S9 mix: 0.01, 0.05, 0.10, 0.15, 0.20 and 0.25 µL/mL (4 h) - Vehicle / solvent:
- - Vehicle/solvent used: DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- other: hycanthone (-S9), 7.5 and 10.0 µg/mL
- Details on test system and experimental conditions:
- TREATMENT AND HARVEST SCHEDULE:
- Exposure duration/duration of treatment: 4 h with and without S9 mix
FOR GENE MUTATION:
- Expression time: 48 h
- Selection time: 14 days
- Fixation time: 16 days
- Selection agent: 1 µg/mL trifluorothymidine (TFT)
- Method to enumerate numbers of viable and mutants cells: relative total growth
METHODS FOR MEASUREMENT OF CYTOTOXICITY
- Method: Relative cloning efficiency, relative total growth
METHODS FOR MEASUREMENTS OF GENOTOXICIY :
- Number and size distribution of small and large colonies and total number of colonies
- Mutant frequency
- Evaluation criteria:
- Colonies in the mutant count and cloning efficiency dishes were counted, and the colonies in the solvent and positive control mutant count plates were sized by hand using a dissecting microscope to enumerate mutant colonies.
- Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 0.02 µL/mL, 0.15 µL/mL
- Vehicle controls validity:
- valid
- Remarks:
- cloning efficiency was below acceptability criteria in the first test; vehicle controls were valid in the second test
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation and time of the determination: In the main mutagenicity study no precipitation was observed, neither in the presence nor in the absence of metabolic activation.
RANGE-FINDING/SCREENING STUDIES:
In the range-finding assay, both in the presence and absence of metabolic activation, there were concentration-related decreases in cell survival. No cells were present in cultures exposed to >0.1 µL/mL in the absence of metabolic activation or in cultures exposed to >1.0 µL/mL with metabolic activation. Slight precipitate was seen without activation at >0.316 µL/mL and with metabolic activation at >0.1 pl/ml. Based on these findings, the first mutagenesis assay was conducted using a concentration range of 0.0001-0.0562 µL/mL without metabolic activating and 0.0562-0.562 µL/mLl with metabolic activation.
STUDY RESULTS:
In the first mouse lymphoma assay, there was a concentration-dependent increase in mutant frequencies, as well as a concentration-dependent increase in induced mutant frequencies (please refer to Table 1 under “Any other information on results incl. tables”). However, no concentration was tested that yielded survival in the 10-20% range. In addition, the average cloning efficiencies of the solvent controls were 62.7% without S9 mix and 55.4% with S9 mix, which were below the acceptability criteria of 70%. Mutant frequencies obtained with the solvent control were high, especially in the presence of metabolic activation, suggesting the preparation may have been mutagenic. For this reason, the mutagenicity assay was repeated.
In the second assay, average cloning efficiencies of solvent controls and spontaneous mutant frequencies were within the expected range. In addition, there was a dose-related decrease in relative total growth and a concentration-related increase in mutant frequency, with and without metabolic activation (please refer to Table 2 under “Any other information on results incl. tables”). The test item induced clear concentration-related increases in induced colonies up to cytotoxic concentrations (relative total growth values ≥ 10%). Further, the test item induced clear increases in small colonies (< 1 mm in diameter) and only relatively slight increases in large colonies, both with and without metabolic activation.
In both experiments, positive controls showed the expected results and were within the range of historical control data (data not provided in publication).
ADDITIONAL INFORMATION ON CYTOTOXICITY:
In a first assay with concentrations of 0.0001 to 0.0562 µL/mL without metabolic activation and 0.0562 to 0.562 µL/mL with metabolic activation no concentration tested yielded survival in the range of 10 to 20%. Aaverage cloning efficiencies of the solvent controls were below the acceptability criteria. Therefore a second assay with concentrations of 0.001 to 0.04 µL/mL without S9 and 0.01 to 0.25 µL/mL with S9 was conducted. The cloning efficiencies of the solvent control in the second test were considered acceptable. - Conclusions:
- Interpretation of results: positive with and without metabolic activation.
Referenceopen allclose all
Table 1:
Summary of Experiment I | |||||||
Metabolic Activation | Test Group | Dose level per plate | Revertant Colony Count (Mean) | ||||
TA1535 | TA1537 | TA98 | TA100 | WP2uvRA | |||
without activation | DMSO | 20 | 10 | 24 | 138 | 39 | |
Untreated | 18 | 13 | 28 | 146 | 43 | ||
MMP | 3 µg | 16 | 8 | 25 | 127 | 40 | |
10 µg | 19 | 11 | 20 | 139 | 40 | ||
33 µg | 17 | 10 | 30 | 129 | 41 | ||
100 µg | 19 | 9 | 28 | 121 | 41 | ||
333 µg | 21 | 9 | 33 | 121 | 39 | ||
1000 µg | 23 | 12 | 21 | 138 | 54 | ||
2500 µg | 8 | 6 | 10 | 1 | 41 | ||
5000 µg | 1P | 1P | 1P | 0P | 2P | ||
NaN3 | 10 µg | 1612 | 2374 | ||||
4-NOPD | 10 µg | 378 | |||||
4-NOPD | 50 µg | 79 | |||||
MMS | 2.0 µL | 1085 | |||||
with activation | DMSO | 15 | 11 | 37 | 127 | 49 | |
Untreated | 19 | 16 | 34 | 128 | 56 | ||
MMP | 3 µg | 16 | 15 | 36 | 127 | 47 | |
10 µg | 19 | 10 | 39 | 126 | 47 | ||
33 µg | 15 | 11 | 37 | 134 | 48 | ||
100 µg | 19 | 10 | 41 | 126 | 55 | ||
333 µg | 19 | 13 | 38 | 107 | 52 | ||
1000 µg | 20 | 13 | 29 | 99 | 48 | ||
2500 µg | 20 | 8 | 23 | 96 | 52 | ||
5000 µg | 2P | 3P | 1P | 1P | 34P | ||
2-AA | 2.5 µg | 362 | 369 | 3793 | 4827 | ||
2-AA | 10.0 µg | 222 |
P: Precipitate, NaN3: sodium azide, 2 -AA: 2- aminoanthracene, 4 -NOPD: 4 -nitro-o-phenylene-diamine, MMS: methyl methane sulfonate
Table 2:
Summary of Experiment II | |||||||
Metabolic Activation | Test Group | Dose level per plate | Revertant Colony Count (Mean) | ||||
TA1535 | TA1537 | TA98 | TA100 | WP2uvRA | |||
without activation | DMSO | 10 | 8 | 24 | 93 | 41 | |
Untreated | 14 | 16 | 21 | 105 | 41 | ||
MMP | 3 µg | 10 | 7 | 18 | 93 | 38 | |
10 µg | 8 | 9 | 23 | 100 | 39 | ||
33 µg | 12 | 10 | 27 | 98 | 35 | ||
100 µg | 13 | 10 | 27 | 105 | 42 | ||
333 µg | 14 | 8 | 30 | 120 | 44 | ||
1000 µg | 13 | 4 | 16 | 116 | 51 | ||
2500 µg | 3 | 1 | 7 | 2 | 6 | ||
5000 µg | 0P | 0P | 5 | 0P | 0P | ||
NaN3 | 10 µg | 1302 | 2050 | ||||
4-NOPD | 10 µg | 538 | |||||
4-NOPD | 50 µg | 119 | |||||
MMS | 2.0 µL | 736 | |||||
with activation | DMSO | 13 | 13 | 30 | 94 | 45 | |
Untreated | 12 | 15 | 40 | 90 | 48 | ||
MMP | 3 µg | 17 | 17 | 32 | 95 | 49 | |
10 µg | 14 | 11 | 30 | 101 | 44 | ||
33 µg | 13 | 13 | 27 | 94 | 54 | ||
100 µg | 15 | 12 | 32 | 103 | 53 | ||
333 µg | 12 | 12 | 29 | 93 | 41 | ||
1000 µg | 15 | 14 | 35 | 90 | 43 | ||
2500 µg | 9 | 11 | 3 | 6 | 46 | ||
5000 µg | 0P | 0P | 0P | 0P | 0P | ||
2-AA | 2.5 µg | 305 | 349 | 3950 | 2831 | ||
2-AA | 10.0 µg | 225 |
P: Precipitate, NaN3: sodium azide, 2 -AA: 2- aminoanthracene, 4 -NOPD: 4 -nitro-o-phenylene-diamine, MMS: methyl methane sulfonate
Table 1: Experimental results
Pre-incubation test |
||||||||||
Strain | TA 98 | TA 100 | TA 1535 | TA 1537 | TA 1538 | |||||
Metabolic activation | without S9 | with S9 | without S9 | with S9 | without S9 | with S9 | without S9 | with S9 | without S9 | with S9 |
Vehicle control | ||||||||||
DMSO mean | 25 | 41 | 97 | 103 | 14 | 28 | 13 | 29 | 21 | 32 |
± SD | ± 4.6 | ± 6.6 | ± 12.8 | ± 7.2 | ± 3.1 | ± 12.6 | ± 4.5 | ± 6.4 | ± 7.8 | ± 5.1 |
Test item [µg/plate] | ||||||||||
0.01 mean | 16 | 31 | 76 | 99 | 19 | 24 | 14 | 15 | 15 | 26 |
± SD | ± 4.2 | ± 4.4 | ± 5.5 | ± 5.9 | ± 2.5 | ± 2.9 | ± 3.8 | ± 4.2 | ± 5.5 | ± 7.0 |
0.0316 mean | 19 | 31 | 65 | 97 | 16 | 20 | 13 | 19 | 16 | 28 |
± SD | ± 4.7 | ± 4.0 | ± 6.7 | ± 17.8 | ± 6.0 | ± 7.0 | ± 3.0 | ± 6.0 | ± 3.8 | ± 4.0 |
0.1 mean | 15 | 31 | 58 | 100 | 22 | 18 | 11 | 17 | 17 | 24 |
± SD | ± 4.5 | ± 4.0 | ± 6.4 | ± 5.8 | ± 5.3 | ± 5.3 | ± 3.2 | ± 0.6 | ± 1.2 | ± 5.9 |
0.316 mean | 29 | 34 | 65 | 109 | 22 | 20 | 7 | 13 | 13 | 24 |
± SD | ± 2.3 | ± 4.0 | ± 15.0 | ± 7.0 | ± 1.2 | ± 0.6 | ± 2.6 | ± 3.8 | ± 3.5 | ± 1.5 |
Positive control | ||||||||||
mean | 314 | 1012 | 1160 | 2413 | 1248 | 479 | 1256 | 435 | 507 | 1785 |
± SD | ± 10 | ± 116 | ± 194 | ± 352 | ± 173 | ± 58 | ± 89 | ± 21 | ± 104 | ± 269 |
Table 1: Experimental results, first mouse lymphoma assay
Test group | RSG (%) | RTG (%) | MF x 106 | IMF x 106 |
Without metabolic activation, 4 h exposure | ||||
DMSO control | ||||
10 | 88.8 | 90.9 | 81 | - |
10 | 111.2 | 108.6 | 82 | - |
Test item [µL] | ||||
0.0001 | 88.1 | 97.7 | 92 | 11 |
0.0010 | 75.7 | 98.4 | 87 | 6 |
0.0100 | 71.4 | 88.8 | 63 | - |
0.0178 | 52.1 | 62.7 | 107 | 26 |
0.0316 | 33.7 | 37.6 | 116 | 35 |
0.0562 | 0.8 | - | - | - |
HC 7.5 µg | 26.9 | 14.5 | 685 | 604 |
HC 10.0 µg | 23.5 | 12.1 | 690 | 609 |
With metabolic activation, 4 h exposure | ||||
DMSO control | ||||
10 | 112.3 | 104.0 | 291 | - |
10 | 87.7 | 94.2 | 363 | - |
Test item [µL] | ||||
0.05620 | 86.0 | 94.7 | 361 | 34 |
0.10000 | 80.5 | 91.3 | 364 | 37 |
0.17800 | 76.2 | 72.9 | 381 | 54 |
0.31600 | 52.9 | 55.7 | 356 | 29 |
0.56200 | 14.9 | 6.7 | 596 | 269 |
CP 2.5 µg | 50.2 | 19.2 | 862 | 535 |
CP 3.75 µg | 47.2 | 2.7 | 977 | 650 |
HC: Hycanthone, CP: Cyclophosphamide, RSG: relative suspension growth, RTG: relative total growth, MF: mutant frequency, IMF: induced mutant frequency
Table 2: Experimental results, second mouse lymphoma assay
Test group | RSG (%) | RTG (%) | MF x 106 | IMF x 106 | Colony formation MF x 106 | ||
small | large | total | |||||
Without metabolic activation, 4 h exposure | |||||||
DMSO control | |||||||
10 | 102.0 | 105.2 | 70 | - | 31 | 34 | 70 |
10 | 98.0 | 94.9 | 58 | - | 28 | 30 | 58 |
Test item [µL] | |||||||
0.0010 | 89.7 | 101.0 | 56 | - | 24 | 39 | 56 |
0.0100 | 81.0 | 106.5 | 77 | 13 | 43 | 34 | 77 |
0.0150 | 61.0 | 71.0 | 94 | 30 | 69 | 25 | 94 |
0.0200 | 57.9 | 47.7 | 117 | 53 | 86 | 30 | 117 |
0.0250 | 45.0 | 35.2 | 144 | 80 | 118 | 26 | 144 |
0.0300 | 28.0 | 17.4 | 174 | 110 | 123 | 51 | 174 |
0.0350 | 17.7 | 8.0 | 281 | 217 | 217 | 64 | 281 |
0.0400 | 7.7 | 2.4 | 545 | 482 | 427 | 115 | 545 |
HC 7.5 µg | 46.1 | 33.0 | 296 | 233 | 203 | 93 | 296 |
HC 10.0 µg | 50.4 | 27.0 | 289 | 225 | 211 | 78 | 289 |
With metabolic activation, 4 h exposure | |||||||
DMSO control | |||||||
10 | 88.2 | 97.2 | 43 | - | 22 | 20 | 43 |
10 | 111.8 | 100.4 | 47 | - | 22 | 24 | 47 |
Test item [µL] | |||||||
0.010 | 99.9 | 91.4 | 41 | - | 15 | 26 | 41 |
0.050 | 89.2 | 81.9 | 26 | - | 16 | 10 | 26 |
0.100 | 68.4 | 48.3 | 67 | 23 | 52 | 15 | 67 |
0.150 | 45.9 | 27.0 | 85 | 40 | 59 | 26 | 85 |
0.200 | 23.5 | 11.5 | 228 | 184 | 194 | 35 | 228 |
0.250 | 10.2 | 2.4 | 647 | 602 | 538 | 109 | 647 |
CP 2.5 µg | 97.7 | 40.2 | 221 | 176 | 177 | 44 | 221 |
CP 3.75 µg | 61.1 | 14.5 | 317 | 272 | 269 | 48 | 317 |
HC: Hycanthone, CP: Cyclophosphamide, RSG: relative suspension growth, RTG: relative total growth, MF: mutant frequency, IMF: induced mutant frequency
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Genetic toxicity in vivo
Description of key information
Genotoxicity in somatic cells in vivo (OECD 474, Micronucleus test): negative for clastogenicity in CD-1 mice
Genotoxicity in somatic cells in vivo (OECD 474, Micronucleus test): positive for clastogenicity C57BL mice, genotoxic effect attributed to impurity acrolein
Link to relevant study records
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1994-06-20 to 1994-06-24
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- other: TSCA Test Guidelines, Federal Register, Vol. 50, #188, Part 798
- Version / remarks:
- adopted 27 Sep 1985
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Version / remarks:
- adopted 29 Jul 2016
- Deviations:
- yes
- Remarks:
- no information on generation of the test atmosphere, analytical determination of impurities in the atmosphere, no historical control data, bone marrow toxicity / exposure not evident
- GLP compliance:
- yes
- Type of assay:
- mammalian erythrocyte micronucleus test
- Species:
- mouse
- Strain:
- C57BL
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 23.8 - 33.0 g (males) and 21.9 - 26.5 g (females)
- Housing: individually in stainless steel cages
- Diet: Purina Rodent Laboratory Chow, ad libitum
- Water: ad libitum
- Acclimatisation period: up to 7 days
- Route of administration:
- inhalation
- Vehicle:
- air
- Details on exposure:
- Groups of 5 animals of each sex were exposed nose only, 1 h on two consecutive days to atmospheres containing 37.4, 88.5, 155.6 ppm. Analytical determination of the test compound by GC was mentioned, but the records were not included in the report.
- Duration of treatment / exposure:
- 2 days
- Frequency of treatment:
- 1 h exposure per day on 2 consecutive days
- Post exposure period:
- 24 h
- Dose / conc.:
- 50 ppm (nominal)
- Remarks:
- corresponding to analytical concentrations of 37.4 ppm or 161.6 mg/m3 air
- Dose / conc.:
- 100 ppm (nominal)
- Remarks:
- corresponding to analytical concentrations of 88.5 ppm or 382 mg/m3 air
- Dose / conc.:
- 150 ppm (nominal)
- Remarks:
- corresponding to analytical concentrations of 155.6 ppm or 672 mg/m3 air
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- triethylenemelamine
- Route of administration: intraperitoneal injection, single application on study Day 2
- Doses / concentrations: 0.4 mg/kg bw - Tissues and cell types examined:
- Tissue: bone marrow
Cell type: bone marrow cells - Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION: Dose levels were chosen based on a preliminary range-finding study
TREATMENT AND SAMPLING TIMES:
Two single doses were administered, one on each of two consecutive days. Sampling was performed 24 h after the last dose.
DETAILS OF SLIDE PREPARATION:
2-3 µL of blood per slide was obtained from the mid-ventral tail vein of a mouse and placed on top of the serum. The blood was mixed with the serum and spread on the slide to produce a thin, even film, then the slide was allowed to air dry. Three slides were prepared per mouse, and after the slides were dry, the erythrocytes were fixed by placing the slides in absolute methanol for two minutes and air-dried. The slides were stained for 20 minutes in 5% Giemsa stain in phosphate buffer containing 3% methanol and 3% 0.1M citric acid, rinsed by dipping them in deionized water until clear, and allowed to air dry.
METHOD OF ANALYSIS:
For each animal, 1000 polychromatic and 1000 normochromatic erythrocytes were scored for the presence of micronuclei. In addition, the proportion of polychromatic (immature) among total (polychromatic + normochromatic) erythrocytes was determined for each animal by counting a total of 1000 erythrocytes.
- Sex:
- male/female
- Genotoxicity:
- positive
- Toxicity:
- no effects
- Remarks:
- assessed by PCE/NCE ratios
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF DEFINITIVE STUDY:
- Induction of micronuclei: Significant elevation of micronucleated PCEs was observed in males of the low and high dose group, but initially not of the middle dose group. When 1000 additional PCEs were evaluated in the mid dose male mice and the negative control an increase was also observed at this dose level. In female mice the number of micronuclated PCEs was not elevated significantly compared to the negative controls. The result in females was considered equivocal by the authors.
- Ratio of PCE/NCE: A dose related depression in PCE/NCE ratios was seen in female mice, however they were higher than the untreated controls. In male mice no clear dose related depression in PCE/NCE ratios was observed.
- Clinical signs of toxicity: No toxic symptoms were noted in the treated animals. - Conclusions:
- Interpretation of results: positive. According to the authors an impurity in the sample might have caused the positive result. However, no further evidence was provided for this statement.
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1999-11-18 to 2000-01-27
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Version / remarks:
- adopted 21 Jul 1997
- Deviations:
- yes
- Remarks:
- high mortality at 200 mg/kg bw/day, thus only 2 valid dose levels were used
- Qualifier:
- according to guideline
- Guideline:
- other: ICH Tripartite Harmonised Guideline on Genotoxicity: Specific Aspects of Regulatory Tests
- Version / remarks:
- adopted 1995
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese MAFF
- Version / remarks:
- adopted 1990
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS-42193 Mammalian Eryhtrocyte Micronucleus Test
- Version / remarks:
- adopted Aug 1997
- GLP compliance:
- yes
- Type of assay:
- mammalian erythrocyte micronucleus test
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK Ltd, Margate, UK
- Weight at study initiation: 22 - 31 g (males) and 21 - 27 g (females)
- Assigned to test groups randomly: yes
- Housing: in groups of no more than three animals of the same sex in appropriate caging, cleaned and dried before use
- Diet: laboratory chow diet (Special Diets Services Ltd), ad libitum
- Water: tap water, ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 - 24
- Humidity (%): 54 - 61
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- intraperitoneal
- Vehicle:
- - Vehicle(s)/solvent(s) used: corn oil
- Concentration of test material in vehicle: 2.5, 5.0 and 10.0 mg/mL - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Dosing formulations were made by mixing the test item with corn oil. Dilutions were made using corn oil. The test article formulations were inverted periodically during dosing and used within approximately 2.75 hours of initial formulation.
- Duration of treatment / exposure:
- 2 days
- Frequency of treatment:
- administration of 2 doses, 24 h apart
- Post exposure period:
- 24 h
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 6
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- cyclophosphamide
- Route of administration: intraperitoneal injection
- Doses / concentrations: 40 mg/kg bw, single administration - Tissues and cell types examined:
- Tissue: bone marrow
Cell type: bone marrow cells - Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
A range finding study was performed to find the maximum tolerated dose.
TREATMENT AND SAMPLING TIMES:
Two single doses were administered, one on each of two consecutive days. Sampling was performed 24 h after the last dose.
DETAILS OF SLIDE PREPARATION:
The cells were centrifuged and the serum was aspirated to leave one or two drops and the cell pellet. The pellet was mixed into this small volume of serum and the suspension was dropped on each of two coded slides. Slides were allowed to air-dry and fixed for 5 min in absolute methanol. Finally, the slides were stained with Giemsa (1:6 v/v in distilled water), rinsed, air-dried and cleared in xylene for 3 min.
METHOD OF ANALYSIS:
The proportion of polychromatic (immature, PCE) among total (polychromatic + normochromatic (NCE)) erythrocytes was determined for each animal by counting a total of 1000 erythrocytes (PCE + NCE).
2000 polychromatic erythrocytes were counted per animal to determine the presence of micronuclei. - Evaluation criteria:
- A test article is considered as positive in this assay if a statistically significant increase in the frequency of micronucleated PCE occurs at least at one dose, and if the frequency of micronucleated PCE at such a point exceeds the historical vehicle control range.
- Key result
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- clinical signs at 100 and 200 mg/kg bw/day
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY:
Dose levels were chosen based on an initial range finding study with groups of 3 male and female mice at a dose range of 50 to 400 mg/kg bw/day, once daily for two consecutive days. Death of all animals occured at dose levels of 300 and 400 mg/kg bw/day. Clinical symptoms were observed from 100 mg/kg bw/day. Consequently doses of 50, 100 and 200 mg/kg bw/day were chosen for the main study.
RESULTS OF DEFINITIVE STUDY
- Induction of micronuclei: The test item did not induce a statistically significant increase in the frequency of micronucleated PCEs up to 200 mg/kg bw/day. Group mean frequencies of micronucleated PCE were also similar to that seen in the vehicle controls. The number of micrunucleated PCE of the control animals fell within the historical control rate. The positive control substance induced a statistically significant increase in the frequency of micronucleated PCEs.
- Ratio of PCE/NCE: PCE/NCE ratios of the treated animals were similar to those of the vehicle controls.
- Statistical evaluation: Chi-square test
MORTALITY: Several animals (6/6 males and 2/6 females) of the high dose group died prior to the sampling time.
CLINICAL SIGNS: Clinical symptoms were observed at 100 and 200 mg/kg bw/day. At 100 mg/kg bw/day, lethargy and eye closure were noted. At 200 mg/kg bw/day, the animals showed abnormal breathing, lethargy, eye closure, prostration and abnormal gait. - Conclusions:
- Interpretation of results: negative
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Genetic toxicity in vitro:
In vitro gene mutation in bacteria:
The test item was investigated for the mutagenic potential in a Bacterial Reverse Mutation Assay (Ames test) performed according to OECD guideline 471 and in compliance with GLP (2020 -5042 -DGM). S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 uvrA were exposed to the test in item in triplicates in the presence and absence of metabolic activation (S9 mix).
Based on a plate incorporation pre-experiment with and without metabolic activation, concentrations for the main mutation assay were selected at 3 – 5000 μg/plate. The pre-experiment was reported as experiment I. A pre-incubation test with the same concentrations with and without metabolic activation served as experiment II. Solvent (DMSO) and appropriate positive controls were included. After 48 h of incubation at 37 °C, all plates were inspected for bacterial background lawn and the number of revertant colonies was determined.
The test item did not induce a biologically relevant increase in the number of revertant colonies in any of the tested strains either with or without metabolic up to the highest tested concentration in the presence and absence of S9 mix. Positive and vehicle controls confirmed the validity of the test system and demonstrated the functionality of the S9 mix. Cytotoxicity was observed at the higher concentrations (2500 µg/plate). Precipiation of the test material was observed at the top dose of 5000 µg/plate.
Thus, under the experimental conditions chosen, the test item is not mutagenic in bacteria with and without metabolic activation.
In a second Ames test (Ballantyne 2000) the test substance did not show mutagenic activity in Salmonella typhimurium TA1535, TA1537, TA1538, TA98 or TA100 with and without metabolic activation.
In vitro gene mutation in mammalian cells:
The mutagenic potential of the test item in vitro was investigated in a mouse lymphoma assay (94-0198-FKM). In an experimental procedure similar to OECD guideline 476, mouse lymphoma L5178Y TK+/- cells were exposed to the test item (purity of 97.1%), vehicle (DMSO) or positive controls in the presence and absence of metabolic activation (S9 mix). The cells were exposed for 4 h to concentrations in the range of 0.0001 – 0.0562 µL/mL in the absence of S9 mix and to concentrations in the range of 0.0562 – 0.562 µL/mL in the presence of metabolic activation in experiment I. The cells were exposed for 4 h to concentrations in the range of 0.001 – 0.040 µL/mL in the absence of S9 mix and to concentrations in the range of 0.01 – 0.25 µL/mL in the presence of metabolic activation in experiment II.
In experiment I, there was a concentration-dependent increase in mutant frequencies, as well as a concentration-dependent increase in induced mutant frequencies. However, no concentration was tested that yielded survival in the 10-20% range. In addition, the average cloning efficiencies of the solvent controls were 62.7% without S9 mix and 55.4% with S9 mix, which were below the acceptability criteria of 70%. Mutant frequencies obtained with the solvent control were high, especially in the presence of metabolic activation, suggesting the preparation may have been mutagenic. For this reason, the mutagenicity assay was repeated.
In experiment II, average cloning efficiencies of solvent controls and spontaneous mutant frequencies fell within the expected range. In addition, there was a dose-related decrease in relative total growth and a concentration-related increase in mutant frequency, with and without metabolic activation. The test item induced clear concentration-related increases in induced colonies up to cytotoxic concentrations (relative total growth values ≥ 10%). The test item induced clear increases in small colonies (< 1 mm in diameter) and only relatively slight increases in large colonies, both with and without metabolic activation.
Cytotoxicity was observed at concentrations in the range of 0.015 – 0.04 µL/mL. The positive controls (hycanthone without S9 mix and cyclophosphamide with S9 mix) demonstrated the validity of the test. The increase in mutation frequency was almost exclusively attributable to an increase in sigma-colonies indicating that the test substance primarily induced chromosomal aberrations in this test system. Lambda colonies were only increased at the highest concentrations tested (survival rate below 3%). Under the conditions of the test, the experimental findings indicate a mutagenic potential of the test item. However, acrolein is present in the test substance as an impurity (0.05%). It is unclear if acrolein contributes to the genotoxic effects observed in the test.
Genetic toxicity in vivo:
Two micronucleus tests in vivo are available.
In a guideline study performed similar to OECD guideline 474 and in compliance with GLP, the test item (99.8% purity) was dissolved in corn oil and administered intraperitoneally to CD1 mice (99-0098-DGM). Based on the results of a preliminary range-finding study, dose levels for the mutagenicity study were selected. Groups of 6 mice/sex received two injections on two consecutive days at doses of 50, 100 and 200 mg/kg bw. A group of 6 mice served as positive control and received 40 mg/kg bw cyclophosphamide. 24 h after the last injection, bone marrow smears were prepared. For each animal, 2000 polychromatic erythrocytes were screened for the presence of micronuclei and 1000 erythrocytes per mouse were scored for the ratio of polychromatic (PCE) to normochromatic (NCE) erythrocytes.
6/6 males and 2/6 females of the high dose group died prior to the sampling time. Clinical symptoms were observed at 100 and 200 mg/kg bw: lethargy and eye closure at 100 mg/kg bw, and abnormal breathing, lethargy, eye closure, prostration and abnormal gait at 200 mg/kg bw.
There were no treatment-related changes in the frequency of micronucleated PCEs. The test item did not induce a statistically significant increase in the frequency of micronucleated PCEs up to 200 mg/kg bw. Group mean frequencies of micronucleated PCE were also similar to that seen in the vehicle controls and fell within the range of historical control data.
The positive control substance induced a statistically significant increase in the frequency of micronucleated PCEs, thus demonstrating the sensitivity of the test system. Under the conditions of the mentioned study, the test item has no genotoxic potential in vivo.
A second, less reliable mouse micronucleus study was conducted following TSCA test guideline, Fed. Reg. 50 § 188 part 798 and GLP using a test substance with purity 97.1 % (94-0214-DGM). Groups of 5 male and 5 female C57BL mice were exposed by inhalation (nose only) to concentrations of 37.4, 88.5 and 155.6 ppm (analytical concentration) for 1 h on 2 consecutive days. Negative controls were exposed to air. 24 h after the last exposure blood was collected from the animals and the peripheral erythrocytes were examined for micronuclei (number of cells evaluated was not specified in the study report). No clinical effects were observed in the exposed animals. A dose-related decrease in the PCE/NCE ratio was reported for female animals only, but the ratio was higher than in controls. A significant increase of the number of micronucleated polychromatic erythrocytes was reported in the high and low dose males, but not in the females. An additional evaluation of 1000 PCEs in the mid dose males resulted also in a significantly increased rate of micronucleated PCEs. Several deficiencies compared with the current OECD guideline were noted. The number of erythrocytes counted per animal is not given and the number of PCEs counted is lower than recommended. There are big inter-individual differences between the number of micronuclei/1000 PCEs in the dose groups. With regard to males of all dose groups, 1 to 3 animals did not have an increased amount of micronucleated PCEs, while the ratio varied between 2.5 and 15 in the other animals. A dose-related increase in micronuclei and statistically significant increase in micronucleated PCEs was observed in low-, mid-, and high-dose males. Considering the deficiencies, the results of this study are regarded as equivocal.
Conclusion:
In conclusion, the available experimental data on gene mutation in vivo and in vitro revealed equivocal results. There was no evidence for genotoxicity in bacteria (Ames test). A positive result for genotoxicity in mammalian cells in vitro was obtained in a mouse lymphoma assay, in which an increase in mutations for sigma colonies was indicative of a clastogenic effect in vitro in the absence of S9 mix. In the presence of S9 mix, significant increases in mutation rates were only observed at highly cytotoxic concentrations. Acrolein is present in the test substance as an impurity, it is unclear if acrolein contributes to the genotoxic effects observed in the test. However, the concentration of acrolein in the batch used in the test is similar to the concentration of acrolein given in the substance composition and the result of the in vitro mouse lymphoma assay can be considered relevant. A guideline-compliant in vivo micronucleus test with test material of an analytical purity of 99% was negative for mutagenicity in vivo, indicating that the clastogenic effects that was demonstrated in vitro did not occur in vivo. In a second micronucleus assay which suffered from a number of deficiencies and inconsistencies and a the test material of reduced purity (97 - 97.8%) revealed an equivocally positive results. It was unclear whether the genotoxic effects can be attributed to the acrolein, which is present in the test substance as an impurity.
Justification for classification or non-classification
The available information on genotoxicity in vitro (Ames test and mouse lymphoma assay) and in vivo (micronucleus test) do not require classification according to Regulation No. (EC) 1272/2008.
No classification for genetic toxicity is warranted according to the criteria of the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.